Luigi Meneghini, MD

Luigi Meneghini, MD, MBA

Endocrinology Dallas, TX

Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center, Executive Director, Global Diabetes Program, Parkland Health & Hospital System


Office Address

  • 5323 Harry Hines Blvd
    Dallas, TX 75390
    Phone: (214) 648-3494

Luigi Meneghini, MD, MBA

Endocrinology Dallas, TX

Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center, Executive Director, Global Diabetes Program, Parkland Health & Hospital System

Clinical Specialties & Interests

  • Endocrinology: Diabetes
  • Clinical Interests: Diabetes; Insulin management; Type 2 Diabetes Mellitus; Hypoglycemic Agents; Insulin; Blood Glucose; Type 1 Diabetes Mellitus; Glycosylated Hemoglobin A; Treatment Outcome; Long-Acting Insulin

Education & Training

  • Jackson Memorial Hospital - Jackson Health SystemJackson Memorial Hospital - Jackson Health System
  • University of MiamiUniversity of Miami
  • University of Miami School of BusinessUniversity of Miami School of Business
  • Jackson Memorial Hospital - Jackson Health SystemJackson Memorial Hospital - Jackson Health System
  • Jackson Memorial Hospital - Jackson Health SystemJackson Memorial Hospital - Jackson Health System
  • Emory University School of MedicineEmory University School of Medicine
  • Emory UniversityEmory University

Certifications & Licensure

  • TX State Medical LicenseTX State Medical License2014 - 2016
  • FL State Medical LicenseFL State Medical License1990 - 2017

      Awards, Honors, & Recognition

      • Who’s Who in AmericaMarquis, 2013-2014
      • The Leading Physicians of the WorldInternational Association of Healthcare Professionals, 2013-2014
      • Top Doctors:South FloridaCastle Connolly, 2012

      Publications & Presentations

      PubMed

      Journal Articles

      • Barriers to Initiating Insulin in Type 2 Diabetes Patients: Development of a New Patient Education Tool to Address Myths Misconceptions and Clinical Realities  Brod M, Alolga SL, Meneghini L, The Patient, 6/1/2014
      • SOLVE Study Group Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents (OHAs) in routine clinical practice  Ross S, Dzida G, Ji Q, Kaiser M, Ligthelm R, Meneghini L, Nazeri A, Orozco-Beltran D, Pan C, Svendsen AL, J Diabetes, 5/1/2014
      • A patient-level analysis of efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine added to oral antidiabetes agents in people with ty...  DeVries H, Meneghini L, Barnett AH, Reid T, Dain MP, Landgraf W, Vlajnic A, Traylor L, Bergenstal RM, European Endocrinology, 1/1/2014

      Books/Book Chapters

      • Type 1 Diabetes in Adults: Principles and Practice Chapter: Pathophysiology of Type 1 diabetes 
        Meneghini LF
        Editors: Jabbour & Stephens.Informa Healthcare USA, Inc, New York, NY
        2008

      Abstracts/Posters

      • Lower within-subject variability in mean blood glucose concentration with insulin degludec vs. in-sulin glargine: a meta-analysis of patients with T2D Meneghini L, Harris S, Evans M, Rasmussen S, Johansen T, Pieber T, World Diabetes Congress, 12/1/2013
      • Reduced risk of hypoglycaemia with insulin degludec vs. insulin glargine in patients with type 2 diabetes and a BMI >30 kg/m2: a meta-analysis of five randomised tr... Philis-Tsimikas A, Rodbard HW, Meneghini LF, Kapur K, Endahl L, Russell-Jones DL, World Diabetes Congress, 12/1/2013
      • Reduced Risk of Hypoglycemia with Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes and a BMI >30 kg/m(2): A Meta-analysis of 5 Randomized Trials Rodbard HW1, Meneghini LF, Russell-Jones DL, Kapur R, Endahl L, Kapor J, Philis-Tsimikas A, Can J Diabetes, 10/1/2013

      Lectures

      • Inpatient management of diabetes 12/1/2013
      • Ultra-Long Acting Basal Insulin Analogs: Challenges & Opportunities 11/1/2013
      • Advances in GLP1 Therapy: Current Agents and Combinations 11/1/2013

      Other

      • Update on the use of detemir insulin in the management of type 2 diabetes Meneghini LF, Sheik A, US Endocrinology
        1/1/2008
      • Managing Type 2 Diabetes in Ethnic Minority Populations Kahn K, Meneghini L, Clinical Medicine Today: Diabetes Newsletter
        1/1/2008
      • Current Treatment Options for a Type 2 Diabetes Patient Not Controlled on OADs Meneghini LF, Pri-Med Online
        http://www.pri-med.com
        1/1/2008

      Other Languages

      • Spanish, French, Italian

      Insurance Accepted

      • Aetna Choice POS II
      • Aetna HMO
      • AvMed Health Open Access
      • BCBS Blue Card PPO
      • BCBS California CaliforniaCare HMO
      • BCBS California PPO
      • BCBS Florida BlueCare HMO
      • BCBS Florida NetworkBlue
      • BCBS Florida Preferred Patient Care PPO
      • Blue Shield California HMO
      • Blue Shield California PPO
      • CIGNA HMO
      • CIGNA Open Access
      • CIGNA PPO
      • Coventry Florida - Employer Group HMO/Open Access
      • Coventry Florida - Employer Group PPO
      • First Health PPO
      • Great West PPO
      • Health Net California Large Group PPO
      • Humana ChoiceCare Network PPO
      • Multiplan PHCS PPO
      • Multiplan PHCS PPO - Kaiser
      • Multiplan PPO
      • Pacificare HMO
      • United - River Valley Neighborhood Health Partnership
      • United Healthcare - Direct Choice Plus POS
      • United Healthcare - Direct Options PPO
      • WEA Trust Preferred Provider Plan - Trust Pref

      Medical Groups

      • University of Miami Med Grp

      Links

      • The full profile is locked and available to verified physicians only.
        Join over 50% of U.S. physicians already on Doximity and get access to this and over 700,000 physician CVs. Find your physician profile

      Physicians, view Dr. Meneghini's full Doximity profile to:

      • Trade HIPAA-secure messages
      • Send and receive online faxes
      • Refer a patient
      • See their complete CV